Research summary
Research HubHMG (Human Menopausal Gonadotropin)
Clinical — 10 studies
HMG is a hormone preparation containing FSH and LH activity, studied in reproductive and endocrine research.
Being studied for
- Gonadotropin signaling research
- Endocrine axis studies
Published Research
Evidence profile
Controlled human evidence
10 cited publications · 5 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial
Li J et al. · Journal of assisted reproduction and genetics · 2025
The study reportedApplication of 5.0 mg LE followed with HMG does not improve the pregnancy rate compared to 2.5 mg LE in infertile women with PCOS. An increased dose of LE to 5.0 mg may increase the risks of OHSS and multiple pregnancies. Therapy of LE (2.
Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles
Kaplan PF et al. · American journal of obstetrics and gynecology · 2000
The study reportedSubcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination treatment cycles was generally well tolerated and yielded stimulation parameters and pregnancy rates similar to those associated with the intramuscular route.
Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization
Maroulis GB et al. · Fertility and sterility · 1991
The study reportedThese findings suggest that there is no obvious superiority between the two GnRH-a protocols in the dosage schedule used and that the major advantage of GnRH-a over non-GnRH-a protocols is in decreasing the cancellation rate and increasing the number of oocytes and conceptus obtained.
Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression
Edelstein MC et al. · Fertility and sterility · 1990
The study reportedThere were no significant differences between hMG and FSH cycles with regard to the day of hCG administration, mean peak estradiol levels, number of ampules of medication used, and number of oocytes aspirated, embryos transferred, or pregnancies.
Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis
Dahan MH et al. · Gynecologic and obstetric investigation · 2026
The study reportedThe higher number of oocytes retrieved with r-hFSH:r-hLH is a pertinent finding, owing to the well-established positive association between oocyte number and reproductive outcomes.
Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation
Levi Setti PE et al. · Journal of endocrinological investigation · 2015
The study reportedRecombinant follicle-stimulating hormone treatment resulted in a higher oocytes yield per cycle than human menopausal gonadotropin at similar cost per oocyte.
Additional indexed literature (4)
- Clinical · Mechanistic studyRandomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection
Witz CA et al. · Fertility and sterility · 2020 · PMID 32416978
- Preclinical · Mechanistic studyComparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection
Korucu DG et al. · Ceska gynekologie · 2024 · PMID 39800543
- Preclinical · Mechanistic studyLuteinizing hormone supplementation with human menopausal gonadotropin versus low dose human chorionic gonadotropin during ovarian stimulation does not affect live birth rates after fresh and frozen embryo transfer
Fischer L et al. · The journal of obstetrics and gynaecology research · 2024 · PMID 39245464
- Preclinical · Primary trialThe effect of human menopausal gonadotropin and equine chorionic gonadotropin on the reproductive performance of treated ewes with short-term progesterone injections and sponge during the non-breeding season
Sorkh SDG et al. · Reproduction in domestic animals = Zuchthygiene · 2024 · PMID 38426383
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.